Shandong Huaxin Pharmaceutical Group Co., Ltd. is a comprehensive pharmaceutical enterprise integrating scientific research and development, pharmaceutical manufacturing, and pharmaceutical economy and trade
Founded in March 2002 and headquartered in Heze High-tech Industrial Park, Shandong Huaxin Pharmaceutical Group has 10 dosage forms, including glue, large-volume injection, tablet, granule, capsule and oral solution, all of which have successfully passed the new GMP certification at one time. After more than ten years of ups and downs, CEFC Group has completed a beautiful transformation like a phoenix, and has grown from a little-known small factory to a modern comprehensive pharmaceutical group integrating scientific research and development, pharmaceutical manufacturing, and pharmaceutical economy and trade.
Since its establishment, Shandong Huaxin Pharmaceutical Group has taken "building a national brand" as its own responsibility, vigorously developed the Ejiao industry, increased the market development and expansion of Huaxin Ejiao series products, carried out deep cultivation of the target market, implemented the marketing strategy of all employees, took Ejiao as the brand based variety, and worked with major chain distributors and retailers to build a chain terminal market in 100 cities and 100,000 families, grasped the development of the terminal market and the channel network construction with the provincial region as the unit, and continuously launched the national food health word Ejiao health care products and Ejiao food. Pay attention to the large-scale operation and standardized operation of Ejiao series products, realize the operation of the whole Ejiao industry chain, and make CEFC Group develop steadily in the pattern of deep processing of Ejiao products, diversification of industrial structure, serialization of products, and maximization of capital returns.
CEFC Group has newly launched the main product group of upper respiratory tract infection - exclusive patented products, three types of national new drugs: Longxiang Ping Asthma Capsule, Pseudo Menamine Capsule, Meiyu Pseudo Ma Oral Liquid and other products are the new varieties that the company has focused on cultivating in the past two years, which is also the company's new economic growth point, and the marketing strategy in the country is being comprehensively promoted, and gradually build a sales network and channels covering all levels of hospitals and community outpatient clinics centered on prefecture-level cities. The clinical terminal products based on the new drug Longxiang Pingchuan Capsule, Yizhong Shengxue Capsule, Zidan Huoxue Capsule, Pseudomesamine Capsule, Meiyu Pseudohemp Oral Solution, and decoction piece gelatin are constantly refreshing sales records, continuing to increase market share, and achieving new breakthroughs in the terminal market.
Huaxin Pharmaceutical Group will continue to do a good job in product structure adjustment, enterprise transformation and upgrading, focus on the main products (ejiao, new drugs), implement the development strategy of large varieties, large terminals and great health, standardize the operation of enterprises, establish and improve the modern enterprise system, connect with the capital market, establish and improve the quality control system of the whole process of drugs, implement refined management and intelligent manufacturing, and consistently pursue the safety and significant functional efficacy of drugs, so as to achieve the new take-off of Huaxin.
